62 research outputs found
Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro
Some biologics can modulate cytokines that may lead to changes in expression of drugmetabolizing
enzymes and cause drug-drug interactions (DDI). DDI potential of TV-
1106—an albumin-fused growth hormone (GH)—was investigated. In this study, human
blood was exposed to recombinant human growth hormone (rhGH) or TV-1106, followed
by isolation of the plasma and its application to human hepatocytes. While the
treatment of blood with rhGH increased multiple cytokines, treatment of blood with
TV-1106 had no effect on any of the nine cytokines tested. The interleukin (IL)-6 concentration
was higher in the rhGH then in the TV-1106-treated plasma (P < .05). While
rhGH had little or no effect on CYP1A2 or CYP2C19 mRNA but increased CYP3A4
mRNA twofold, TV-1106 had little or no effect on cytochrome P450 (CYP) mRNAs in
hepatocytes. Although the plasma from rhGH-treated blood lowered CYP1A2 activity,
the TV-1106 plasma had no effect on CYP activities. The CYP1A2 activity was lower in
the rhGH- then in the TV-1106-plasma treated hepatocytes (P < .05). The results indicated
that fusing GH with albumin made TV-1106 an unlikely participant of CYP1A2,
CYP2C19 or CYP3A4-facilitated, direct or cytokine-driven DDI.The authors would like to thank scientists in the Scientific Operations
at Sekisui XenoTech for their technical assistance
Gene Expression Patterns in Myelodyplasia Underline the Role of Apoptosis and Differentiation in Disease Initiation and Progression
The myelodysplastic syndromes (MDS) are clonal stem cell disorders, characterized by ineffective and dysplastic hematopoiesis. The genetic and epigenetic pathways that determine disease stage and progression are largely unknown. In the current study we used gene expression microarray methodology to examine the gene expression differences between normal hematopoietic cells and hematopoietic cells from patients with MDS at different disease stages, using both unselected and CD34+ selected cells. Significant differences between normal and MDS hematopoietic cells were observed for several genes and pathways. Several genes promoting or opposing apoptosis were dysregulated in MDS cases, most notably MCL1 and EPOR. Progression from RA to RAEB(T) was associated with increased expression of several histone genes. In addition, the RAR-RXR pathway, critical for maintaining a balance between self-renewal and differentiation of hematopoietic stem cells, was found to be deregulated in hematopoietic cells from patients with advanced MDS compared to patients with refractory anemia. These findings provide new insights into the understanding of the pathophysiology and progression of MDS, and may guide to new targets for therapy. Taken together with previous published data, the present results also underscore the considerable complexity of the regulation of gene expression in MDS
Differentiation of Human Cytomegalovirus Genotypes in Immunocompromised Patients on the Basis of UL4 Gene Polymorphisms
Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission
Individualized Assessment of Exercise Capacity in Response to Acute and Long-Term Enzyme Replacement Therapy in Pediatric Pompe Disease
Background: Enzyme replacement therapy (ERT) with alglucosidase alfa improves the prospect of patients with infantile-onset Pompe disease (IOPD). However, a progressive decline has been reported. Objective quantification of the response to ERT when assessing newer strategies is warranted. Methods: This combined retrospective-prospective study assessed the acute and long-term effects of ERT on exercise in IOPD patients. Evaluation included cardiopulmonary exercise testing (CPET), 6-min walking test (6MWT), spirometry, motor function test (GMFM-88) and enzyme blood levels. Results: Thirty-four CPETs (17 pre- and 17 two days-post ERT) over variable follow-up periods were performed in four patients. Two days following ERT, blood enzyme levels increased (median, 1.22 and 10.15 μmol/L/h (p = 0.003)). However, FEV1, FVC and GMFM-88, the median 6MWD and the peak VO2 were unchanged. Long-term evaluations showed stabilization in young patients but progressive deterioration in adolescents. Clinical deterioration was associated with more pronounced deterioration in peak VO2 followed in the decreasing order by 6MWD, FVC and GMFM-88. Conclusions: The peak VO2 and 6MWD might serve as more sensitive markers to assess clinical deterioration. More studies are needed to clarify the sensitivity of the peak VO2 and 6MWT for quantification of individualized response. This may be important when assessing newer strategies and formulations in IOPD
- …